Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: Experience of the Brazilian Wilms' tumor study group

Authors:
  • RMRenato Melaragno
    Renato Melaragno
  • NSNagsla Saba E Silva
    Nagsla Saba E Silva
  • NMNubia Mendoncla
    Nubia Mendoncla
  • MAMaria Nunes Alvares
    Maria Nunes Alvares
  • EMElizabeth Morinaka
    Elizabeth Morinaka
  • AMArmando Marques
    Armando Marques
  • MCMaria P. Cusato
    Maria P. Cusato

Abstract
A total of 15 patients with relapsed Wilms' tumor were treated with carboplatin as a single agent. There were six females and nine males, aged between 2 and 9 years (me‐dian:5). The treatment consisted of carboplatin given I.V. as a single agent at a dose of 550 mg/m2 over 1 hour every 3 weeks. There were four (26%) complete responses, four (26%) partial responses, one stable disease, and six with progressive disease. In all patients a total of 56 courses were given and the toxicities found were leukopenia and thrombocytopenia. The overall response rate was encouraging and the toxicity was acceptable and reversible.

This publication has 10 references indexed in Scilit: